Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions
- Written by PR Newswire
- SK bioscience invested USD 3 million in FinaBio, a U.S. company specializing in next-generation conjugate vaccine technology.
- With the agreement, SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines, including those for pneumoniae and typhoid.
- The company will accelerate its future growth strategies by exploring...













